Chronic kidney disease (CKD) is a global health issue. Kidney failure patients may undergo a kidney transplantation (KTX) and prescribed an immunosuppressant medication i.e., tacrolimus. Tacrolimus’ efficacy and toxicity varies among patients. This study investigates the cost-utility of pharmacogenomics (PGx) guided tacrolimus treatment compared to the conventional approach in Austrian patients undergone KTX, participating in the PREPARE UPGx study. Treatment’s effectiveness was determined by mean survival, and utility values were based on a Visual Analog Scale score. Incremental Cost-Effectiveness Ratio was also calculated. PGx-guided treatment arm was found to be cost-effective, resulting in reduced cost (3902 euros less), 6% less hospitalization days and lower risk of adverse drug events compared to the control arm. The PGx-guided arm showed a mean 0.900 QALYs (95% CI: 0.862–0.936) versus 0.851 QALYs (95% CI: 0.814–0.885) in the other arm. In conclusion, PGx-guided tacrolimus treatment represents a cost-saving option in the Austrian healthcare setting.

慢性肾脏病（CKD）是一个全球性的健康问题。肾衰竭患者可能会接受肾移植（KTX）并服用免疫抑制剂，即他克莫司。他克莫司的疗效和毒性因患者而异。本研究调查了参与 PREPARE UPGx 研究的奥地利患者接受 KTX 后，药物基因组学 (PGx) 指导下的他克莫司治疗与传统方法相比的成本效益。治疗的有效性由平均生存率决定，效用值基于视觉模拟量表评分。还计算了增量成本效益比。研究发现，与对照组相比，PGx 引导的治疗组具有成本效益，可降低成本（减少 3902 欧元）、减少 6% 的住院天数以及降低药物不良事件的风险。PGx 引导组的平均 QALY 为 0.900（95% CI：0.862–0.936），而另一组为 0.851 QALY（95% CI：0.814–0.885）。总之，PGx 引导的他克莫司治疗在奥地利医疗机构中是一种节省成本的选择。